About aquestive therapeutics inc - AQST
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.
AQST At a Glance
Aquestive Therapeutics, Inc.
30 Technology Drive
Warren, New Jersey 07059
| Phone | 1-908-941-1900 | Revenue | 44.55M | |
| Industry | Pharmaceuticals: Major | Net Income | -83,784,000.00 | |
| Sector | Health Technology | Employees | 147 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
AQST Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 15.507 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -10.146 |
| Enterprise Value to Sales | 15.737 |
| Total Debt to Enterprise Value | 0.188 |
AQST Efficiency
| Revenue/Employee | 303,027.211 |
| Income Per Employee | -569,959.184 |
| Receivables Turnover | 2.508 |
| Total Asset Turnover | 0.338 |
AQST Liquidity
| Current Ratio | 3.135 |
| Quick Ratio | 3.006 |
| Cash Ratio | 2.545 |
AQST Profitability
| Gross Margin | 61.49 |
| Operating Margin | -156.359 |
| Pretax Margin | -188.088 |
| Net Margin | -188.088 |
| Return on Assets | -63.57 |
| Return on Equity | N/A |
| Return on Total Capital | -85.684 |
| Return on Invested Capital | -114.524 |
AQST Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 134.425 |
| Total Debt to Total Assets | 81.053 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 122.537 |